Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | GLA | P06280 | 3/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | HPGD | P15428 | 3/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.78 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.78 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.78 |
| ▸ | GCGR | P47871 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561714 | 0.96 | KDM4E (0.72) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL2593317 | 0.93 | KDM4E (0.91) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL11176392 | 0.89 | MAPK13 (1.00) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL29103864 | 0.89 | KDM4E (0.83) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561570 | 0.87 | KDM4E (0.62) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL29642733 | 0.86 | KDM4E (1.00) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL16497610 | 0.86 | MAPK14 (0.81) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561692 | 0.85 | MAPK13 (1.00) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561579 | 0.84 | KDM4E (0.76) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12311111 | 0.84 | KDM4E (0.75) | KDM4EKMT2AALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8394815-B2 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents | LORUS THERAPEUTICS INC. (CA) | 2013-03-12 | — | — | US | disclosed |
| US-8394815-B2 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents | LORUS THERAPEUTICS INC. (CA) | 2013-03-12 | — | — | US | disclosed |
| US-20110152337-A1 | 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS | LORUS THERAPEUTICS INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-7884120-B2 | microbiocides such as 2-(2-methyl-1H-indol-3-yl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole; bactericides; fungicides | LORUS THERAPEUTICS INC. (CA) | 2011-02-08 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2005047266-A9 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070105929-A1 | 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents | APTOSE BIOSCIENCES INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20070105929-A1 | 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents | APTOSE BIOSCIENCES INC. (CA) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152337-A1 | 2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS | IDO2, ERG28, IL4 | KDM4E 745/4885KMT2A 2279/4885ALDH1A1 2832/4885 |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | KDM4E 551/4885KMT2A 396/4885ALDH1A1 1142/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | KDM4E 566/4885KMT2A 362/4885ALDH1A1 1330/4885 |
| US-20070105929-A1 | 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents | IDO2, ERG28, IL4 | KDM4E 745/4885KMT2A 2279/4885ALDH1A1 2832/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | KDM4E 551/4885KMT2A 396/4885ALDH1A1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.